Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Amortization of Deferred Charges (2019 - 2024)

ImmunityBio (IBRX) has disclosed Amortization of Deferred Charges for 4 consecutive years, with $5.0 million as the latest value for Q4 2024.

  • On a quarterly basis, Amortization of Deferred Charges fell 29.66% to $5.0 million in Q4 2024 year-over-year; TTM through Sep 2025 was $5.0 million, a 79.73% decrease, with the full-year FY2024 number at $22.6 million, down 46.72% from a year prior.
  • Amortization of Deferred Charges was $5.0 million for Q4 2024 at ImmunityBio, down from $6.2 million in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $12.3 million in Q2 2023 to a low of -$936000.0 in Q3 2022.
  • A 3-year average of $6.8 million and a median of $6.0 million in 2024 define the central range for Amortization of Deferred Charges.
  • Peak YoY movement for Amortization of Deferred Charges: soared 3017.84% in 2023, then tumbled 52.54% in 2024.
  • ImmunityBio's Amortization of Deferred Charges stood at $11.0 million in 2022, then crashed by 35.53% to $7.1 million in 2023, then fell by 29.66% to $5.0 million in 2024.
  • Per Business Quant, the three most recent readings for IBRX's Amortization of Deferred Charges are $5.0 million (Q4 2024), $6.2 million (Q3 2024), and $5.8 million (Q2 2024).